Lung Cancer Clinical Trial
Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer
This is a blood collection study being conducted to better understand and describe the immunological blood profile changes in patients with advanced non small cell lung cancer undergoing treatment with checkpoint inhibitor therapy. Blood will be collected from healthy volunteers and patients with non small cell lung cancer
≥ 18 years old at the time of informed consent
Written informed consent and HIPAA authorization for release of personal health information.
Subjects with histologically and radiographically confirmed NSCLC.
Subjects must have stage IV disease or recurrent disease.
Subjects should be treatment naïve (systemic therapies) or have received prior chemotherapy in the first line setting. Prior radiation or surgery is permissible.
Subjects who are eligible to receive single agent immunotherapy must have documentation of a PD-L1 Tumor Proportion Score (TPS) of at least 1%.
Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Subjects with curable or potentially curable NSCLC.
Subjects should not have contraindications to treatment with immune checkpoint inhibitors per standard criteria.
Patients with targetable mutations eligible for treatment with molecularly targeted small molecule inhibitor therapy.
Subjects eligible for combination treatment with chemoimmunotherapy.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Indianapolis Indiana, 46202, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.